

KEY FACTS

CHAIRMAN & CEO:

Howard Solomon

YEAR FOUNDED:

1954 (incorporated 1956)

EMPLOYEES (GLOBAL):

5,000

SALES FORCE:

3,000

STOCK EXCHANGE LISTING:

New York Stock Exchange (FRX)

WEBSITE:

www.FRX.com

COMPANY

Forest Laboratories offers prescription medications that have a meaningful impact on people's lives. Our quest to deliver quality products is driven by entrepreneurial spirit, commitment to integrity, and deep respect for people and community.

BUSINESS MODEL

Forest Laboratories partners with pharmaceutical and biotech companies worldwide to develop its marketed products, licensing or acquiring promising new products from innovative companies at virtually every stage of development. Forest conducts rigorous scientific investigation of its licensed drugs, and executes focused marketing and sales initiatives to firmly establish its products in the marketplace.

PRINCIPAL BRANDS

Forest Laboratories' growing line of key products includes:

- **Bystolic**[®] (nebivolol), a beta blocker indicated for the treatment of hypertension; may be used alone or in combination with other antihypertensive agents
- **Campral**^{®*} (acamprosate calcium), a glutamate receptor modulator, indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
- **Lexapro**[®] (escitalopram oxalate), an SSRI antidepressant indicated for acute and maintenance treatment of major depressive disorder in adults and in adolescents, 12 to 17 years of age, and the acute treatment of generalized anxiety disorder in adults
- **Namenda**[®] (memantine HCl), an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease
- **Savella**[™] (milnacipran HCl), a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia

PIPELINE

Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories. Forest's current product pipeline includes therapies in all stages of development and across a wide range of therapeutic areas. The following is a partial listing of our compounds in development and several supplemental indications currently under investigation for our approved products (in alphabetical order):

- **Aclidinium** for chronic obstructive pulmonary disease
- **Aclidinium + formoterol** for chronic obstructive pulmonary disease
- **Cariprazine** for schizophrenia and bipolar disorder
- **Ceftaroline acetate** for complicated skin and skin structure infections and community acquired pneumonia for hospitalized patients
- **Ceftaroline + NXL104** for hospital infections
- **Daxas** for chronic obstructive pulmonary disease
- **Dutogliptin** for diabetes
- **F2695** for depression
- **Linaclotide** for chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C)
- **Memantine ER**, a once-daily formulation for the treatment of moderate to severe Alzheimer's disease
- **Nebivolol** for congestive heart failure
- **Oglemilast** for chronic obstructive pulmonary disease
- **Radiprodil** for pain

*Campral is a registered trademark of Merck Santé s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

SALES AND MARKETING

Forest Laboratories has a long history of success conducting effective marketing and sales initiatives to position its products in the marketplace. In the United States, Forest markets its prescription products through its subsidiary Forest Pharmaceuticals, Inc., and several dedicated specialty sales teams. Generic products are marketed by Forest's subsidiary Inwood Laboratories, Inc. In the United Kingdom, Ireland, and certain export markets, Forest products are marketed directly by subsidiaries Forest Laboratories UK, Ltd, and the Tosara Group.

FINANCIALS

For fiscal year ending March 31, 2009, Forest reported \$3,922,782,000 in net revenue, \$767,743,000 in net income, and earnings per common and common equivalent shares (diluted) of \$2.52.

LOCATIONS

CORPORATE HEADQUARTERS:

909 Third Avenue
New York, NY 10022
1- 800-947-5227 *Toll-free* | 1-212-421-7850
www.frx.com

IN THE US:

Jersey City, NJ
Commack, NY
Farmingdale, NY
Hauppauge, NY
Oakland, CA
St. Louis, MO
Cincinnati, OH

IN EUROPE:

Ireland
United Kingdom

CONTACT

INVESTORS & MEDIA

Frank J. Murdolo, Vice President – Investor Relations
Forest Laboratories, Inc.
1-212-224-6714
Frank.Murdolo@frx.com

PHYSICIANS

Medical Information and Communication
1-800-678-1605, ext. 66297